Dr Lal Pathlabs Ltd Share Price

Q: What is the share price of Dr Lal Pathlabs Ltd today?

Dr Lal Pathlabs Ltd share price as on 22 Jan 2025 is ₹2842.85

Diagnostic Services

NSE: LALPATHLAB Small Cap ISIN: INE600L01024

As on 22 January 2025 at 15:52 IST

₹2,842.85

+ 48.55

(1.74%)

Sell Buy

About Dr Lal Pathlabs Ltd

Dr Lal PathLabs Ltd is India's leading diagnostic and related healthcare testing provider. It operates in the healthcare sector. Dr Lal PathLabs has been in business since 1949. This long history of many decades underscores the company’s experience and reliability. The headquarters of Dr. Lal PathLabs is located in New Delhi, India, serving as the central hub for its extensive network of laboratories and collection centers. Dr Lal PathLabs offers a wide array of diagnostic products and services. These include blood tests, urine tests, and tests on other human body viscera. Read More...

Over 1 Month

-5.16%

Over 6 Months

-8.87%

Over 1 Year

17.85%

Over 3 Years

-7.27%

Dr Lal Pathlabs Ltd Summary

Close ₹ 2,842.85

Open ₹ 2,808.40

High ₹ 2,850

Low ₹ 2,794.30

Volume 1,64,288

Net Turnover (in ₹) ₹ 36,36,60,492.20

52Wk High ₹ 3,653.95

52Wk Low ₹ 1,943.70

52Wk High / Low

1,943.70

3,653.95

Dr Lal Pathlabs Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 23,356.92

EPS (TTM) 52.15

Book Value (BV) 248.16

Div. Yield 0.64 %

P/E (TTM) 53.58

Price/Book Value 11.26

Delivery % 44.98 %

Face Value 10

Key Ratios

PE Ratio 49.15

PB Ratio 9.94

EV to Sales 9.33

PEG Ratio 1.57

ROA 18.07

ROE 21.42

Debt-Equity 0.12

Net Profit Margin 19.54

Operating Profit Margin 31.49

Dr Lal Pathlabs Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	2,295.81	2,058.60	2,139.95	1,632.60	1,385.40
Total Expenses	1,790.36	1,714.77	1,664.97	1,238.19	1,074.90
Profit Before Tax	505.45	343.83	474.98	394.41	310.50
Profit After Tax	362.29	241.08	350.29	296.48	227.59
Operating Profit after Depreciation	534.81	381.36	505.16	410.41	325.81

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	1,195.52	1,307.03	1,369.37	450.74	414.01
Total Non Current Assets	1,329.27	1,412.48	1,471.60	516.16	481.66
Total Current Assets	1,126.70	973.09	875.15	1,145.17	892.65
TOTAL ASSETS	2,455.96	2,385.56	2,346.75	1,661.33	1,374.31
Total Shareholder's Fund	1,849.28	1,666.30	1,501.61	1,245.06	1,032.81

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	535.33	456.03	446.69	398.15	283.89
Net Cash used in Investing Activities	-24.27	-287.31	-449.25	-212.02	-26.11
Net Cash used in Financing Activities	-413.86	-283.18	136.45	-138.56	-190.45

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	2,026.86	1,815.63	1,931.89	1,541.82	1,331.21
Total Expenses	1,510.89	1,424.80	1,470.90	1,167.78	1,028.46
Profit Before Tax	515.97	390.83	460.99	374.04	302.75
Profit After Tax	384.37	292.36	345.25	280.11	223.18
Operating Profit after Depreciation	542.81	425.21	489.62	388.87	317.41

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	310.67	363.45	370.95	303.55	297.52
Total Non Current Assets	1,494.89	1,510	1,511.47	483.78	455.52
Total Current Assets	920.55	810.17	699.31	1,089.30	862.41
TOTAL ASSETS	2,415.44	2,320.17	2,210.78	1,573.08	1,317.93
Total Shareholder's Fund	1,899.66	1,689.86	1,472.12	1,217.09	1,016.28

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	477.60	427.53	425.73	373.36	271.99
Net Cash used in Investing Activities	31.91	-288.47	-448.53	-195.19	-19.47
Net Cash used in Financing Activities	-404	-270.05	141.24	-135.74	-187.22

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	660.20	601.90	545.40	538.90	601.30
Total Expenses	457.70	431.90	400.70	398.30	423.50
Profit Before Tax	183.10	149.90	119.90	115.90	152.20
Profit After Tax	130.80	107.80	85.80	82.20	110.70
Operating Profit after Depreciation	224.40	190.60	163.10	158.90	195.90

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	583.90	534.50	479	476	531.70
Total Expenses	399.40	379	348.70	345.90	368.70
Profit Before Tax	183.30	161	120.50	119.50	150.90
Profit After Tax	135.20	122.90	89.50	88.30	113
Operating Profit after Depreciation	206.50	184.30	146.20	145.20	177.10

Dr Lal Pathlabs Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 2,762.45

S2 2,730.60

S3 2,686.50

Pivot 2,806.55

R1 2,838.40

R2 2,882.50

R3 2,914.35

Moving Average

20 SMA 2,924.30

50 SMA 2,985.31

100 SMA 3,147.73

200 SMA 2,951.08

Dr Lal Pathlabs Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Dr Lal Pathlabs Ltd

₹6/Share

Announcement Date 05 Nov 2024

Record Date 05 Nov 2024

Div Yield 60%

AGM Date: 30 Jun 2022

AGM 30/06/2022 Please take note that the Board of Directors in their meeting held today i.e. May 17, 2022 approved following matters: 1. The Audited Standalone and Consolidated Financial Results ('Results') of the Company for the Quarter and Financial Year ended March 31, 2022. A copy of the signed Results along with Auditors Report and Declaration in respect of Audit Report with unmodified opinion under Regulation 33 of the Listing Regulations is attached herewith as Annexure-A. Please take note that the Board of Directors in their meeting held today i.e. May 17, 2022 approved, convening of 28th Annual General Meeting (AGM) of the Company on Thursday June 30, 2022 through Video Conferencing/Other Audio Visual Means (VC/OVAM). pursuant to Regulation 42 of Listing Regulations, the Board of Directors in their meeting held today i.e. May 17, 2022 , fixed June 23, 2022 as the Record Date for the purpose of payment of Final Dividend for Financial Year 2021-22 (if approved by the Shareholders). Please find attached e-copy of newspaper advertisements published in Financial Express and Jansatta on June 9, 2022, intimating about the dispatch of Notice of 28th Annual General Meeting, Annual Report for Financial Year 2021-22 and availability of E-voting facility to the shareholders of the Company. (As Per BSE Announcement dated on 09.06.2022) We wish to inform you that the 28th Annual General Meeting ('AGM') of the Company was held today i.e. Thursday, June 30, 2022 at 10.30 A.M. (IST) through Video Conference in compliance with the provisions of Companies Act, 2013 & circulars issued by Ministry of Corporate Affairs. In this regard, please find enclosed proceedings of the AGM. (As Per BSE Announcement dated on 30.06.2022)

AGM Date: 12 Sep 2023

Board Meeting Outcome of Board Meeting Held on July 27, 2023 Newspaper Advertisement regarding intimation about Annual General Meeting of the Company (As Per BSE Announcement Dated on 15/08/2023) Proceedings of 29th Annual General Meeting (As Per BSE Announcement Dated on 12/09/2023)

AGM Date: 29 Jun 2024

Convening of 30th Annual General Meeting (AGM) of the Company on Saturday, June 29, 2024, through Video Conferencing/ Other Audio-Visual Means (VC/OVAM). Proceedings of the 30th AGM is attached Disclosure is attached (As Per BSE Announcement dated on 29.06.2024)

Dr Lal Pathlabs Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Dr Lal Pathlabs Ltd	₹2,794.35	₹23,357.34
Max Healthcare Institute Ltd	₹1,078.10	₹1,04,805.56
Apollo Hospitals Enterprise Ltd	₹6,918.65	₹99,479.57
Fortis Healthcare Ltd	₹639.80	₹48,302.22
Syngene International Ltd	₹832.10	₹33,495.10
Global Health Ltd	₹1,055.75	₹28,356.11

Dr Lal Pathlabs Ltd News

Dr Lal Pathlabs allots 5,483 equity shares under ESOP

18 Dec 2024, 03:27 pm

Dr Lal Pathlabs allots 3,000 equity shares under ESOP

05 Dec 2024, 06:16 pm

Dr. Lal PathLabs allots Equity shares

Under ESOP

30 Oct 2024, 11:47 am

Board of Dr. Lal PathLabs recommends Second Interim dividend

Of Rs 6 per share

23 Oct 2024, 04:18 pm

Dr. Lal PathLabs to declare Quarterly Result

On 23 October 2024

17 Oct 2024, 03:53 pm

Dr Lal Pathlabs Ltd Stock Analysis

Annual revenue for Dr Lal Pathlabs Ltd increased by 11.63% to ₹2,026.86 crore in FY 2024 from ₹1,815.63 crore in FY 2023.
Annual Net Profit for Dr Lal Pathlabs Ltd increased by 31.47% to ₹384.37 crore in FY 2024 from ₹292.36 crore in FY 2023.
Promoter Shareholding in Dr Lal Pathlabs Ltd decreased by 0.02% in the most recent quarter, from 53.92% in September 2024 to 53.91% in December 2024.
Dr Lal Pathlabs Ltd delivered a 1-year return of 17.85% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Dr Lal Pathlabs Ltd share price moved up by 1.74% from its previous close of INR ₹2,794.30. The latest Dr Lal Pathlabs Ltd share price is INR ₹2,842.85.
Dr Lal Pathlabs Ltd share price today has been at a low of 2,794.30 and a high of 2,850. Over the past 52 weeks, the Dr Lal Pathlabs Ltd share price has seen a low of 1,943.70 and a high of 3,653.95.

About Dr Lal Pathlabs Ltd

Dr Lal PathLabs Ltd is India's leading diagnostic and related healthcare testing provider. The company offers comprehensive diagnostic services, which include routine blood tests. It also provides specialized tests for viral and bacterial infections. These services are crucial for the early detection and management of various health conditions. This makes Dr. Lal PathLabs a vital player in the healthcare sector.

Operating within the healthcare sector, Dr. Lal PathLabs specializes in diagnostics and pathology. The company has been in business since 1949. This long history of many decades underscores the company’s experience and reliability. The headquarters of Dr. Lal PathLabs is located in New Delhi, India. It is the central hub for the company's extensive network of laboratories and collection centers.

The company was founded by the late Dr. S. K. Lal, who laid the foundation for what has become one of India’s most trusted diagnostic service providers. The company's promoters include Arvind Lal with a 30.81% stake. A team of professional managerial promoters manages the operations of the company-

Arvind Lal
Om Prakash Manchanda
Vandana Lal
Rahul Sharma
Archana Lal Erdmann

Dr Lal PathLabs offers a wide array of diagnostic products and services. These include blood tests, urine tests, and tests on other human body viscera. The company also provides specialized tests for diabetes, cancer, and infectious diseases. Additionally, Dr. Lal PathLabs offers preventive health check-up packages under various brand names. These include Swasthfit, Sugarnme, OncoPro, and NephroPro.

While Dr. Lal PathLabs is a significant player in the Indian diagnostics market, it is not currently the largest in terms of market share. Additionally, it does not hold the top position in market capitalization. However, it is recognized for its extensive network and high-quality services.

The registered office of Dr Lal PathLabs Ltd is in Rohini, New Delhi, and the registrar's office is in C-1 Block LS, New Delhi. Dr. Lal PathLabs Ltd is a well-established and trusted name in the Indian healthcare sector. It is known for its comprehensive diagnostic services and commitment to quality and innovation.

Importance of the Dr Lal PathLabs Limited

Dr Lal PathLabs Ltd plays a crucial role in the healthcare sector, particularly in diagnostics and pathology. The company provides a wide range of essential diagnostic services. These services are crucial for the early detection and management of various health conditions. These services include routine blood tests, specialized tests for infections, and preventive screenings. The availability of comprehensive diagnostic services helps in timely diagnosis. This is vital for effective treatment and better health outcomes.

The importance of Dr Lal PathLabs extends beyond just providing diagnostic services. The company has been a pioneer in the Indian diagnostics industry since its inception in 1949. With over seven decades of experience, Dr Lal PathLabs has built a reputation for reliability and quality. This long-standing presence in the market has allowed the company to develop a deep understanding of the population's healthcare needs. As a result, it can offer relevant and high-quality services.

Headquartered in New Delhi, Dr Lal PathLabs operates an extensive network of laboratories and collection centers across India. This widespread presence ensures that people from various regions have access to essential diagnostic services. The company’s network includes over 200 clinical laboratories, over 2,500 patient service centers, and around 6,500 pick-up points. This extensive reach makes it easier for patients to get their tests done conveniently without traveling long distances.

The company was founded by the late Dr. S. K. Lal, a visionary who recognized the need for reliable diagnostic services in India. Today, Dr Lal PathLabs is promoted by Dr. Arvind Lal, who continues to uphold the legacy of quality and innovation established by his father. Under his leadership, the company has embraced modern technologies and practices. This commitment ensures that it remains at the forefront of the diagnostics industry.

The company’s commitment to quality is evident in its accreditation and certifications. Dr. Lal PathLabs is accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL). Additionally, it holds accreditation from the College of American Pathologists (CAP). These accreditations are a testament to the company’s adherence to international standards of quality and reliability. Patients can trust that the test results from Dr Lal PathLabs are accurate and dependable.

While Dr Lal PathLabs is a significant player in the Indian diagnostics market, it is not currently the largest in terms of market share or market capitalization. However, it is recognized for its extensive network and high-quality services. The company’s focus on quality and customer satisfaction has helped it build a loyal customer base.

Promoter shareholding is an essential aspect of Dr Lal PathLabs’ corporate structure. The promoters hold a significant stake in the company, ensuring strong governance and strategic direction. This promoter involvement is crucial for maintaining the company’s vision and values. These values are centered around quality, innovation, and customer satisfaction.

The company also maintains a robust management team and a clear governance framework to ensure transparency and accountability. This solid corporate governance structure helps maintain stakeholders' trust, including patients, investors, and employees.